AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma
The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.
Primary source
ClinicalTrials.gov results record, November 13, 2026
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Read the source: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation